Invex Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IXC.AX research report →
Price Chart
About the company
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials.
- CEO
- Timothy Ryan Slate
- IPO
- 2019
- Employees
- 4
- HQ
- Subiaco, WA, AU
Get TickerSpark's AI analysis on IXC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.02M
- P/E
- -10.81
- PEG
- 0.05
- P/S
- 39.37
- P/B
- 1.98
- EV/EBITDA
- -5.25
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -471.50%
- Net Margin
- -364.89%
- ROE
- -17.07%
- ROIC
- -23.76%
Latest fiscal year · YoY change
- Revenue
- $229.08K-81.1%
- Gross Profit
- $229.08K-81.1%
- Op Income
- $-709,305
- Net Income
- $-476,868+71.0%
- EPS
- $-0.01+71.1%
- OCF Growth
- +73.3%
- FCF Growth
- +73.3%
- 52W High
- $0.18
- 52W Low
- $0.09
- 50D MA
- $0.11
- 200D MA
- $0.11
- Beta
- 0.54
- RSI (14)
- 62
- Avg Volume
- 37.17K
No earnings-call transcripts are available for IXC.AX yet.
- Free Float
- 99.6%
- Shares Outstanding
- 75.15M
- Float Shares
- 74.85M
Our IXC.AX coverage
Recent articles, reports, and earnings notes.
No research on IXC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IXC.AX report →